DARZALEX Q3 Sales Hit $4.24B, Up Sharply From Prior Quarter
GMAB sits 59% above its 52-week low of $23.62.
Summary
Genmab reported worldwide net trade sales of DARZALEX of $4,239 million for Q3 2026, with $2,528 million in the U.S. and $1,711 million in the rest of the world. This is the first disclosure of Q3 sales and follows the company's H1 2026 revenue of $2.05 billion reported in August, indicating continued strong growth in the franchise. Genmab receives royalties on these worldwide net sales from Johnson & Johnson, making this a direct read-through to Genmab's royalty revenue. The figure is materially higher than the $3.5 billion reported for Q2 2026, suggesting accelerating demand for the multiple myeloma therapy. Investors will look for confirmation of the royalty rate and any impact on full-year guidance when Genmab reports Q3 earnings.
At the time of this announcement, GMAB was trading at $37.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $22.1B. The 52-week trading range was $23.62 to $40.17. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.